Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: J Hepatol. 2022 Apr 12;77(3):723–734. doi: 10.1016/j.jhep.2022.03.029

Fig 8. Inhibition of glycolysis by 3PO attenuates liver fibrosis in a 3-week CCl4 model and human liver samples from patients with cirrhosis indicate involvement of CXCl1.

Fig 8.

A. Sirius red staining shows significant attenuation of liver fibrosis in 3PO treated mice after 3-week CCl4 injection compared to non 3PO treated mice (n=3-9, **p<0.01). Right panel shows quantification. B. RNA in situ hybridization of human liver samples from patients with cirrhosis shows significantly increased expression of CXCL1 mRNA in cirrhotic vs non-cirrhotic liver, particularly in LYVE1 positive cells. Right panel shows quantification.